GeneFerm Biotechnology Co Ltd (1796) — Financial Flexibility Index
GeneFerm Biotechnology Co Ltd (1796) has a Financial Flexibility Index of 0.02x as of June 2025. Free cash flow of NT$7.43 Million (operating CF NT$1.45 Million minus capex NT$5.98 Million) represents 0% of total liabilities (NT$453.10 Million). Check GeneFerm Biotechnology Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
GeneFerm Biotechnology Co Ltd Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for GeneFerm Biotechnology Co Ltd across 8 annual periods. See working capital position of GeneFerm Biotechnology Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for GeneFerm Biotechnology Co Ltd (2017–2024)
Year-by-year free cash flow to debt coverage for GeneFerm Biotechnology Co Ltd. For the full company profile including market capitalisation, see GeneFerm Biotechnology Co Ltd stock valuation.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.09x | NT$30.79 Million | NT$8.09 Million | NT$358.31 Million | ▼ -90.7% |
| 2023 | 0.93x | NT$261.72 Million | NT$190.31 Million | NT$282.54 Million | ▼ -17.1% |
| 2022 | 1.12x | NT$400.85 Million | NT$122.43 Million | NT$358.86 Million | ▲ +146.6% |
| 2021 | 0.45x | NT$257.84 Million | NT$112.23 Million | NT$569.22 Million | ▲ +91.4% |
| 2020 | 0.24x | NT$138.74 Million | NT$56.42 Million | NT$586.38 Million | ▼ -84.3% |
| 2019 | 1.51x | NT$69.26 Million | NT$14.69 Million | NT$46.00 Million | ▲ +198.6% |
| 2018 | 0.50x | NT$70.94 Million | NT$42.14 Million | NT$140.69 Million | ▼ -15.9% |
| 2017 | 0.60x | NT$116.23 Million | NT$61.08 Million | NT$193.79 Million | — |